Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Core Insights - Sagimet Biosciences has made significant progress in its clinical programs for MASH and acne, completing a Phase 1 PK trial of denifanstat and resmetirom, with plans to initiate a Phase 2 trial in F4 MASH patients in the second half of 2026 [1][2] - The company has secured a global, exclusive license for innovative forms of resmetirom active pharmaceutical ingredients from TAPI, enhancing its development capabilities [1][10] - Positive topline results from a Phase 3 trial of denifanstat for moderate to severe acne in China have been reported, supporting the NDA accepted by China's NMPA [1][10] Clinical and Regulatory Updates - The Phase 1 PK trial of denifanstat and resmetirom showed good tolerability with no serious adverse events, paving the way for further development in MASH patients with F4 fibrosis [5][10] - A first-in-human Phase 1 trial of TVB-3567, another FASN inhibitor for acne, is currently ongoing [1][5] - The company plans to explore the role of FASN inhibition in acne further in clinical development in 2026 [2] Financial Results - As of December 31, 2025, Sagimet reported cash, cash equivalents, and marketable securities totaling $113.1 million [10][21] - Research and development expenses for the year were $39.1 million, compared to $38.4 million in 2024, indicating a slight increase in investment in R&D [10][19] - The net loss for the year was $51.0 million, an increase from $45.6 million in 2024, reflecting ongoing investment in clinical trials and development [10][19] Upcoming Milestones - Sagimet plans to advance the denifanstat and resmetirom combination into a Phase 2 proof-of-concept trial for F4 MASH patients in the second half of 2026 [1][10] - Following the completion of the Phase 1 trial of TVB-3567, the company anticipates starting a Phase 2 trial in moderate to severe acne patients in 2026 [10][10]